BEIJING – A Chinese pharmaceutical company said on Thursday that the coronavirus vaccine it is currently developing should be ready for worldwide distribution, including to the United States, by early 2021.
Yin Weidong, CEO of SinoVac, has vowed to apply for the U.S. Food and Drug Administration to sell CoronaVac in the United States, should it pass its third and final round of testing in humans. Yin said he has been given the experimental vaccine, too.
“At the very beginning, our strategy was designed for China and for Wuhan,” Yin said, referring to the Chinese city where the virus first emerged. “Our goal is to provide the vaccine to the entire world, including the U.S., EU and others,” Yin said.
Stringent regulations in the U.S., European Union, Japan and Australia have historically blocked the sale of Chinese vaccines. But Yin said that could change. SinoVac is one of China’s top four vaccine candidates along with state-owned SinoPharm, which has two vaccines in development, and military-affiliated private firm CanSino.
More than 24,000 people are participating in clinical trials of CoronaVac in Brazil, Turkey, and Indonesia, with additional trials scheduled for Bangladesh and possibly Chile, Yin said. SinoVac chose those countries because they all had serious outbreaks, large populations and limited research and development capacity, he said.
He spoke to reporters during a tour of a SinoVac plant south of Beijing. Built within a few months from scratch, the plant is designed to enable SinoVac to produce half a million vaccine doses a year. The biosecure facility was busy on Thursday, filling tiny bottles with the vaccine and boxing them. The company projects it will be able to produce a few hundred million doses of the vaccine by February or March of next year.
SinoVac is also beginning to test small doses of CoronaVac on children and the elderly in China after noticing rising numbers of cases globally among those two groups. Yin said that the company will prioritize the distribution of the vaccine to countries hosting human trials of CoronaVac.
While the vaccine has not yet passed phase 3 clinical trials, a globally accepted standard, SinoVac has already injected thousands of people in China under an emergency use provision. Yin said he was one of the first to receive the experimental vaccine months ago along with researchers after phase one and two of the human trials showed no serious adverse effects.
Earlier this year, China permitted the “emergency use” of vaccine candidates for at-risk populations like border personnel and medical workers if companies could show “good safety and good antibodies” from tests of about 1,000 people, Yin said.
SinoVac received approval in June along with SinoPharm and CanSino, and was able to provide tens of thousands of doses of CoronaVac to Beijing’s municipal government, Yin said.
SinoVac employees qualified for emergency use of the vaccine because an outbreak inside the company would cripple its ability to develop a vaccine, he said. About 90% of the company’s staff have received it.“We are confident that our research of the COVI-19 vaccines can meet the standards of the U.S. and EU countries,” Yin said. AP
